> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/senolytic-pulse-protocol.md). # Senolytic Pulse Protocol ### In this section * [Scope and intent](#scope-and-intent) * [Human dosing patterns that inform the framework](#human-dosing-patterns-that-inform-the-framework) * [Product-based conservative translation](#product-based-conservative-translation) * [Dosing guide using these products](#dosing-guide-using-these-products) * [Bioavailability, access, convenience, and supplier trust](#bioavailability-access-convenience-and-supplier-trust) * [COMT note for protocol use](#comt-note-for-protocol-use) * [Product links](#product-links) * [References by category](#references-by-category) {% hint style="info" %} Read [Senescence — The Second Escape Route](/myhealingcommunity-docs/treatment-resistance/treatment-resistance/senescence-the-second-escape-route.md) before using this guide. That page explains why this protocol exists. It covers therapy-induced senescence, how SASP can keep damaged cells biologically active, why some senescent cells may later escape, and why senolytics are framed here as a second-strike follow-up rather than a primary treatment. {% endhint %} ### Scope and intent This guide is designed as a conservative, patient-facing framework for discussing intermittent natural senolytic-style pulses built around liposomal fisetin, liposomal apigenin and quercetin, using currently available human dosing patterns as the foundation. It should be read after [Senescence — The Second Escape Route](/myhealingcommunity-docs/treatment-resistance/treatment-resistance/senescence-the-second-escape-route.md). That background page explains the core logic behind this protocol. Some treatment-stressed cancer cells stop dividing without dying, stay metabolically active, release SASP signals, and may later re-enter growth. This protocol is written as a cautious follow-up framework for that senescent survivor problem. It is not a clinical trial protocol and should be presented as a translational guide rather than as a validated treatment standard.
### Human dosing patterns that inform the framework Two human patterns are the clearest anchors for intermittent natural senolytic use. In the osteoarthritis trial NCT05276895, the natural senolytic arm used quercetin 1250 mg/day plus fisetin 1000 mg/day for 3 consecutive days every 3 weeks over 12 weeks. In fisetin-focused human studies and summaries of Mayo-style senolytic protocols, fisetin has commonly been used at 20 mg/kg/day for 2 consecutive days as a pulse schedule. These human patterns support a "hit-and-run" approach rather than continuous daily use. The practical implication is that intermittent higher-dose exposure is the closest human evidence base currently available for natural senolytic-style protocols. ### Product-based conservative translation The products considered here are **MCS Formulas Fisetin Pro Liposomal**, which provides 150 mg fisetin per capsule with a phospholipid and chitosan LongLifeLipoTech™ delivery system, **MCS Formulas Quercetin & Bromelain**, which provides 400 mg quercetin per capsule with bromelain included to support oral absorption and MCS Formulas Liposomal Pro Apigenin which contains 200mg apigenin in each capsule. Because the fisetin and the apigenin formulas uses a proprietary pro-liposomal phospholipid plus chitosan system intended to improve absorption and circulation time, a conservative translation is more appropriate than trying to capsule-match the non-formulated trial doses one-for-one. Human literature also supports the broader principle that enhanced extract formulations can materially improve oral bioavailability compared with unformulated extracts. A cautious working assumption is to treat the liposomal formulas as potentially more efficient per milligram than standard powder, then begin below the full trial-equivalent load and escalate only if well tolerated. This is especially reasonable for mixed community groups that include older adults, post-treatment cancer survivors, and people with higher inflammatory burden or supplement sensitivity. ### Dosing guide using these formulas #### Option 1: Conservative entry pulse Use this for first exposure, sensitive individuals, older adults with *multi*morbidity, or post-treatment patients where tolerability matters more than intensity. Days 1-2: Fisetin Pro Liposomal 2 capsules twice daily, total 4 capsules/day = 600 mg fisetin/day. Days 1-2: Quercetin & Bromelain 1 capsule twice daily, total 2 capsules/day = 800 mg quercetin/day. Days 1-2: Apigenin Pro Liposomal 2 capsules twice daily, total 4 capsules/day = 800 mg apigenin/day. Take doses approximately morning and early afternoon, ideally away from the evening if sleep sensitivity is a concern. Repeat no more often than once every 4 weeks for an initial 2 to 3 cycles. This entry pulse stays well below the nominal fisetin trial-equivalent target while still preserving the intermittent senolytic-style structure. It also lands quercetin within the range used in multiple human oral studies while keeping total pill burden manageable. #### Option 2: Intermediate pulse Use this when the conservative entry pulse is well tolerated and a stronger trial-aligned exposure is desired. Days 1-2: Fisetin Pro Liposomal 3 capsules twice daily, total 6 capsules/day = 900 mg fisetin/day. Days 1-2: Quercetin & Bromelain 1 capsule three times daily, total 3 capsules/day = 1200 mg quercetin/day. Days 1-2: Apigenin Pro Liposomal 3 capsules twice daily, total 6 capsules/day = 1200 mg apigenin/day. Space doses across morning, midday, and mid-afternoon where possible. Repeat every 3 to 4 weeks. This option approximates the quercetin exposure used in the osteoarthritis senolytic trial and moves fisetin closer to published pulse targets while still accounting for the possibility of better delivery with the liposomal/chitosan system. For many users, this is a more realistic balance between evidence alignment and capsule burden. #### Option 3: Three day quercetin-forward pulse Use this when the aim is to mirror the structure of the osteoarthritis trial more closely, while still applying a conservative translation for formulated fisetin. Days 1-3: Fisetin Pro Liposomal 2 capsules twice daily, total 4 capsules/day = 600 mg fisetin/day. Days 1-3: Quercetin & Bromelain 1 capsule three times daily, total 3 capsules/day = **1200 mg quercetin/day.** Days 1-3: Apigenin Pro Liposomal 2 capsules twice daily, total 4 capsules/day = 600 mg fisetin/day. Repeat every 3 weeks. This preserves the 3-day pulse rhythm of the human Q+F trial and places quercetin close to the studied 1250 mg/day level. It deliberately keeps fisetin and apigenin below a simple capsule-for-capsule conversion of non-formulated trials because the liposomal pro formulation is intended to improve absorption and slower exposure characteristics. *** ### When senolytics cannot work optimally Senolytic-style pulses do an important part of the job: they help push senescent or damaged cells toward apoptosis or other “off” pathways, but the actual clean‑up still depends on immune, liver, kidney, and lymphatic clearance. Anything that markedly suppresses immune function, overwhelms liver and kidney handling, or keeps inflammation chronically high may reduce how efficiently that debris is recognised and removed. Practical “brakes” can include very low vitamin D status (impaired NK‑cell and [macrophage function](/myhealingcommunity-docs/macrophages-in-cancer.md)), very poor sleep, ongoing hepatotoxic drug load, severe constipation, and acute infections or flares where the body is already struggling to keep up with inflammatory clearance. In those situations, it is reasonable to lean into gentler support cycles first and delay or soften a pulse until recovery and basic clearance capacity have improved. *** {% hint style="info" %} #### Temporary marker "flare" after a senolytic pulse When a senolytic-style pulse successfully pushes stressed or senescent cells toward apoptosis, fragments of those dying cells may briefly circulate in blood. Some blood tests can pick that up, including tumour markers and related biomarker panels. In oncology, short-term rises like this are sometimes called a **flare**. They have been reported after effective systemic treatment, even when later imaging shows the treatment is working. That means tumour markers or ctDNA-style measures may briefly rise or look noisier for days to a couple of weeks after a clearance phase, before settling or trending down again. This pattern is not specific to senolytics. It is also not proven for natural senolytic pulses such as fisetin or quercetin. The biological logic is still plausible. If more damaged cells are pushed into an exit pathway at once, more debris may transiently appear in blood. [Related review](https://pmc.ncbi.nlm.nih.gov/articles/PMC9523829/) This is one reason the guide frames senolytics as intermittent pulses rather than continuous daily dosing. Pulses create spaced windows for clearance to catch up. They also reduce the risk of reading a brief marker flare as treatment failure rather than part of a clean-up phase. This is background physiology only. It is not individual medical advice. Any unexpected or worrying marker change still needs clinician informed interpretation alongside imaging, symptoms, and the wider clinical picture. [Tumour marker basics and limits](https://my.clevelandclinic.org/health/diagnostics/24813-tumor-markers) {% endhint %} *** ### Supporting the body’s clean‑up phase Once a pulse has nudged senescent cells towards exit, the priority shifts to helping the body process and escort that cellular debris out as calmly as possible. This is where the “[Category 3: Supporting / Adjunct Roles”](/myhealingcommunity-docs/treatment-resistance/treatment-resistance/senescence-the-second-escape-route.md#category-3-supporting-adjunct-roles) options become especially relevant: they are not senolytics, but they can help the liver, immune system, and clearance pathways cope with the transient increase in senescent‑cell burden. For example, [silymarin/milk thistle](/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology.md) is positioned here for its role in supporting hepatocyte resilience, modulating stress pathways like NF‑κB, and assisting liver handling of increased apoptotic and metabolic load during and after pulses.\ [TUDCA ](https://www.mcsformulas.com/vitamins-supplements/tudca-250-mg/ref/14)is also a great way to support the liver after a senolytic pulse. Vitamin D3 with K2 fits as a background co‑factor for immune surveillance, with human and mechanistic data linking adequate D status to more competent NK‑cell and macrophage function in clearing senescent or apoptotic cells. Gentle movement, hydration, bowel regularity, and prioritising sleep in the 48–72 hours around a pulse can be framed as simple, low‑tech ways of giving efferocytosis, lymphatic flow, and organ clearance the best chance to quietly do their work. #### Trusted supplier MCS states that their apigenin and fisetin purity is tested by Eurofins prior to manufacturing and highlights no fillers are ever used in their capsules. These formulas are delivered in a dry pro-liposomal capsule that combines phospholipids from sunflower lecithin with chitosan to support formation of neutrally charged liposomes. MCS states that this LongLifeLipoTech™ system is intended to maximize absorption and improve biocompatibility, while published fisetin pharmacokinetic literature independently supports the general need for liposomal formulation strategies because unformulated fisetin has poor oral bioavailability. Learn more about the [advantages of liposomal delivery here.](/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds.md) The quercetin product is not liposomal, but pure bromelain extract is included to support quercetin absorption after oral administration. ### COMT note for protocol use Slow-COMT individuals may be more likely to experience overstimulation, irritability, anxiety, or sleep disruption from quercetin-containing pulses because quercetin is commonly described as a COMT-inhibiting flavonoid in genotype-oriented supplement guidance. Fast-COMT individuals often tolerate this category better, but there are no senolytic trials that adjust fisetin or quercetin pulse dosing by COMT genotype. A simple protocol note is to begin with the conservative entry pulse for anyone with known slow COMT, anxiety, insomnia, stimulant sensitivity, or high reactivity to polyphenols. Fisetin-only pulses can also be considered first where quercetin sensitivity is suspected. *** ### Trusted supplier links {% embed url="" %} {% embed url="" %} {% embed url="" %} {% embed url="" %} {% embed url="" %} **MCS Formulas provides the Study Support Group with a 5% Discount Code:** abbey5 ### References by category #### Human senolytic and related dosing patterns * [Effect of Natural Senolytic Agents & NLRP3 Inhibitors on Osteoarthritis](https://clinicaltrials.gov/study/NCT05276895) * [What is Fisetin? Benefits, Dosage, and Risks](https://vitality-pro.com/fisetin/benefits-dosage-side-effects-fis/) * [Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin](https://pmc.ncbi.nlm.nih.gov/articles/PMC9574875/) * [The Therapeutic and Prophylactic Potential of Quercetin against COVID-19](https://pmc.ncbi.nlm.nih.gov/articles/PMC9137692/) * [NCT06003270 | Biological Effects of Quercetin in COPD Phase II](https://clinicaltrials.gov/study/NCT06003270) #### Product specifications and manufacturer pages * [Fisetin Pro Liposomal, 150 mg - MCS Formulas](https://www.mcsformulas.com/vitamins-supplements/fisetin-pro-liposomal/) * [Apigenin Pro Liposomal - MCS Formulas](https://www.mcsformulas.com/vitamins-supplements/apigenin-pro-liposomal/) * [Quercetin & Bromelain, 400 mg, 100 Caps - MCS Formulas](https://www.mcsformulas.com/vitamins-supplements/quercetin-bromelain-400-mg-100-caps/) * [Milk Thistle-Silymarin - MCS Formulas](https://www.mcsformulas.com/en/vitamins-supplements/milk-thistle-silymarin/) * [Vitamin D3 & K2 Liquid Drops - MCS Formulas](https://www.mcsformulas.com/vitamins-supplements/vitamin-d-k2-liquid/) #### Bioavailability background * [Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin](https://pmc.ncbi.nlm.nih.gov/articles/PMC9574875/) * [Fisetin—In Search of Better Bioavailability—From Macro to Nano](https://pmc.ncbi.nlm.nih.gov/articles/PMC10532335/) #### COMT considerations * [COMT: How to Optimize Your Supplements for Your COMT Genotype](https://www.geneticlifehacks.com/comt-and-supplement-interactions/) * [The COMT Gene Your Complete Guide to Understanding, Testing](https://www.seekinghealth.com/blogs/education/the-comt-gene)

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

{% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com. ## Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/senolytic-pulse-protocol.md?ask=&goal= ``` `ask` is the immediate question: it should be specific, self-contained, and written in natural language. `goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.